Selinexor achieved a 35% or greater spleen volume reduction in 17% of patients at week 24, and in 23% at any point during ...

FUSION trial data published show FFRCT added to CCTA safely cut unnecessary catheterizations. One-year results from the ...

New multi-center registry data confirm MAC as the dominant cause of NTM pulmonary disease, while culture conversion with standard therapy still fails in nearly half of patients. This episode, "New ...

In "Why FACT Accreditation Still Matters for CAR T-Cell Therapy," the discussion turns to why FACT accreditation for CAR T-cell therapy access has held up over 25 years.

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...

Individuals with myasthenia gravis (MG) lived 15 to 19 years longer than those with multiple sclerosis (MS), across 4 ...

Hepatitis B elimination requires expanded vaccination, screening, treatment, and education, Helen Nde, MPH, said. Nde framed ...

MINT randomized 238 patients to inebilizumab 300 mg IV vs placebo with a protocol-driven taper to prednisone ≤5 mg/day and ...

China survey reveals what R/R mantle cell lymphoma patients and doctors value after BTK failure—overall survival tops trade-offs despite CRS risk. Despite advances in recent years, treatment choices ...

Children and young adults who were unvaccinated and infected with COVID-19 were at an increased risk of developing ...

FDA approves brepocitinib, the first oral, targeted therapy for adult dermatomyositis, backed by phase 3 VALOR data. For the ...

Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and ...